tbuckley/cabot-search huggingface dataset:
Equity of resource flows for reproductive, maternal, newborn, and child health: are those most in need being left behind?
Authors: Melisa Martinez-Alvarez, Frederik Federspiel, Neha S Singh, Marco Schäferhoff, Miriam Lewis Sabin, Chima Onoka, Sandra Mounier-Jack, Josephine Borghi, Catherine Pitt
Journal: BMJ (2020)

Although equity has improved in recent years, donors and country governments still need to improve the amount and targeting of funding for reproductive, maternal, and child health, say <b>Melisa Martinez-Alvarez and colleagues</b>
Physiotherapy Not Effective for Pediatric Constipation
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TGF-β2 silencing to target biliary-derived liver diseases
Authors: Anne Dropmann, Steven Dooley, Bedair Dewidar, Seddik Hammad, Tatjana Dediulia, Julia Werle, Vanessa Hartwig, Shahrouz Ghafoory, Stefan Woelfl, Hanna Korhonen, Michel Janicot, Katja Wosikowski, Timo Itzel, Andreas Teufel, Detlef Schuppan, Ana Stojanovic, Adelheid Cerwenka, Stefanie Nittka, Albrecht Piiper, Timo Gaiser, Naiara Beraza, Malgorzata Milkiewicz, Piotr Milkiewicz, John G Brain, David E J Jones, Thomas S Weiss, Ulrich M Zanger, Matthias Ebert, Nadja M Meindl-Beinker
Journal: Gut (2020)

TGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases. As we also found upregulated TGFB2 in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), we now fathomed the positive prospects of targeting TGF-β2 in early stage biliary liver disease using the MDR2-KO mice. Specifically, the influence of TgfB2 silencing on the fibrotic and inflammatory niche was analysed on molecular, cellular and tissue levels. TgfB2-induced expression of fibrotic genes in cholangiocytes and hepatic stellate cellswas detected. TgfB2 expression in MDR2-KO mice was blunted using TgfB2-directed antisense oligonucleotides (AON). Upon AON treatment, reduced collagen deposition, hydroxyproline content and αSMA expression as well as induced PparG expression reflected a significant reduction of fibrogenesis without adverse effects on healthy livers. Expression analyses of fibrotic and inflammatory genes revealed AON-specific regulatory effects on Ccl3, Ccl4, Ccl5, Mki67 and Notch3 expression. Further, AON treatment of MDR2-KO mice increased tissue infiltration by F4/80-positive cells including eosinophils, whereas the number of CD45-positive inflammatory cells decreased. In line, TGFB2 and CD45 expression correlated positively in PSC/PBC patients and localised in similar areas of the diseased liver tissue. Taken together, our data suggest a new mechanistic explanation for amelioration of fibrogenesis by TGF-β2 silencing and provide a direct rationale for TGF-β2-directed drug development.
Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii
Authors: V. Aranzana-Climent, J.M. Buyck, Y. Smani, J. Pachón-Diaz, S. Marchand, W. Couet, N. Grégoire
Journal: Clinical Microbiology and Infection (2020)

ObjectivesTo expand on previous reports of synergy between polymyxin B (PMB) and minocycline (MIN) against Acinetobacter baumannii; and to gain insight into the qualitative and quantitative determinants of their synergy.MethodsA semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model was developed on the basis of data from in vitro time-kill experiments with determination of resistant bacterial count to describe the effects of PMB and MIN alone and in combination. The model was enriched by complementary experiments providing information on the characteristics of the resistant subpopulation.ResultsThe model successfully described the data and made possible quantification of the strength of interaction between the two drugs and formulation of hypotheses about the mechanisms of the observed interaction. The effect of the combination was driven by MIN, with PMB acting as an helper drug; simulations at clinically achievable concentrations showed that 1.5 mg/L MIN +0.2 mg/L PMB is expected to produce sustained killing over 30 hours, while 0.3 mg/L MIN +1 mg/L PMB is met by bacterial regrowth. Interaction equations showed that maximal synergy is reached for PMB concentrations ≥0.1 mg/L and MIN concentrations ≥1 mg/L.ConclusionsSemi-mechanistic PK/PD modelling was used to investigate the quantitative determinants of synergy between PMB and MIN on a PMB-resistant A. baumannii strain. The developed model, improving on usual study techniques, showed asymmetry in the drug interaction, as PMB acted mostly as a helper to MIN, and provided simulations as a tool for future studies.
冠動脈分岐部ステント留置における近位最適化を組み合わせたGliderバルーンによる側枝拡張とキッシングバルーン拡張との比較 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Nishihara Masaaki, Murasato Yoshinobu, Mori Takahiro, Takenaka Katsuhiko, Numaguchi Kotaro, Ejima Emiko, Araki Masahiro, Ura Yujiro, Kyohei Meno, Hiyamuta Kouji
Journal: Circulation (2016)
Practical Guide to Health Policy Evaluation Using Observational Data
Authors: John W. Scott, Todd A. Schwartz, Justin B. Dimick
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Time Trend Influence of Socieconomic Status on Survival, Breslow Thickness, Time from Onset of Symptoms and Surgical Resection in Stage I-II Primary Cutaneous Melanoma
Authors: M. Mandala, G. Imberti, D. Piazzalunga, R. Labianca, G. Lucisano, B. Merelli, S. Mosconi, L. Marchesi, A. Gianatti, C. Tondini
Journal: Annals of Oncology (2012)
What type of pancreatic anastomosis is safest following pancreaticoduodenectomy? An invited commentary on “Critical appraisal of the techniques of pancreatic anastomosis following pancreaticoduodenectomy: A network meta-analysis” (Int J Surg 2019;73:72–7)
Authors: Burcin Ekser, Michele Valmasoni
Journal: International Journal of Surgery (2020)
Moving Electrospun Nanofibers and Bioprinted Scaffolds toward Translational Applications
Authors: Tong Wu, Xiumei Mo, Younan Xia
Journal: Advanced Healthcare Materials (2020)

Abstract Over the past two decades, electrospun nanofibers have been actively explored for a range of applications, including those related to biomedicine, environmental science, energy harvesting, catalysis, photonics, and electronics. Regarding biomedical applications, one can readily produce nanofiber‐based scaffolds with controlled compositions, structures, alignments, and functions by varying the material, design of collector, number of spinnerets, and electrospinning parameters. This report highlights both preclinical and translational applications of electrospun nanofibers and bioprinted constructs presented at the 2019 International Conference on Electrospinning, together with some perspectives on their future development.
IL-17C has a pathogenic role in kidney ischemia/reperfusion injury
Authors: Feng Wang, Jianyong Yin, Yingying Lin, Fangfei Zhang, Xuanchen Liu, Guangyuan Zhang, Yiwei Kong, Zeyuan Lu, Rui Wu, Niansong Wang, Tao Xing, Youcun Qian
Journal: Kidney International (2020)
Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG<sub>4</sub>-related disease’ by Simpson <i>et al</i>
Authors: Mikael Ebbo, Benjamin De Sainte-Marie, Romain Muller, Christelle Piperoglou, Aurélie Grados, Frédéric Vély, Nicolas Schleinitz
Journal: Annals of the Rheumatic Diseases (2020)

Comment on article: 'Dupilumab as a novel steroid-sparing treatment for IgG 4 -related disease' by Simpson et al We read with interest the letter by Simpson et al reporting the use of dupilumab in a patient with IgG 4 -related disease (IgG 4 -RD). 1 Indeed blocking the IL-4/IL-13 pathway is tempting, considering the roles of these cytokines and the physiopathological changes observed during IgG 4 -RD. 2 3We have also treated with dupilumab a 51-year-old man with IgG 4 -related dacryoadenitis and sialadenitis (bilateral lacrimal, parotid, sublingual and submandibular involvement, pattern of Mikulicz syndrome).Left submandibular salivary gland and two cervical lymph nodes biopsies concluded, respectively, to lymphoplasmacytic polyclonal infiltration and reactive hyperplasia. CorrespondenceFigure 1 (A) Patient's initial clinical findings before dupilumab treatment showed bilateral parotid (black arrows), sublingual (white arrow), submandibular glands and cervical lymph nodes involvements.(B) 18 FDG-PET/CT scan before and 6 months after dupilumab treatment alone showed no improvement of salivary glands and lymph nodes involvements.(C) Proportion over time under dupilumab of T helper (Th)1 (IFNg + ), Th2 (IL4 + ) and Th17 (IL17 + ) cells among T CD3 + CD4 + cells; and proportion over time under dupilumab of T follicular helper (Tfh)1 (CD4 + CXCR5 + PD-1 high CXCR3 + CCR6 -), Tfh2 (CD4 + CXCR5 + PD-1 high CXCR3 -CCR6 -) and Tfh17 (CD4 + CXCR5 + PD-1 high CXCR3 -CCR6 + ) cells among Tfh (CD4 + CXCR5 + PD-1 high ) cells.(D) Absolute plasmablast (PB) (CD19 + CD27 high CD38 high ) and Tfh (CD4 + CXCR5 + PD-1 high ) count (10 3 /mL) at baseline (month 0) and under dupilumab (months 3, 6 and 8).(E) Serum IgG 4 (g/L) and IgE (10 2 kIU/L) levels at baseline (month 0) and under dupilumab (months 3 and 8).IFNg, interferon gamma; IL4, interleukin-4.on August 12,
Retrospective review of patients treated with intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy for locally advanced thyroid cancer: The Dana-Farber experience.
Authors: Swati Kodali, Sewanti Atul Limaye, Aditya V. Shreenivas, Dave Zhao, Jochen H. Lorch, Roy B. Tishler, Danielle Nina Margalit, Marshall R. Posner, Robert I. Haddad
Journal: Journal of Clinical Oncology (2012)

e16060 Background: Chemotherapy has been used concurrently with radiation for local control as adjuvant treatment or for locally recurrent thyroid cancer. We present our experience using IMRT with or without sensitizing concurrent chemotherapy in this setting. Methods: All patients with thyroid carcinoma with or without minimal metastatic disease treated since 2005 at DFCI were reviewed. We collected data and analyzed the outcomes of patients treated with IMRT with or without concurrent chemotherapy for local control. Results: Twenty-two patients were identified: 13 Males, 9 Female, Median age 60 years There were 11 papillary, 6 medullary, 4 anaplastic, and1 follicular. Thirteen patients were treated adjuvantly, seven for locally recurrent disease and two definitively for unresectable disease. All patients with papillary and follicular thyroid cancer had prior surgery and radioactive iodine therapy. Patients with medullary carcinoma had surgery alone. Two patients with anaplastic carcinoma had surgery and two were found to be unresectable.. Seventeen patients received concurrent weekly carboplatin AUC1.5 and paclitaxel 30mg/m 2 with radiation. Five patients did not receive any concurrent chemotherapy and were treated with radiotherapy alone. Radiation fields encompassed the thyroid bed, bilateral neck and in some cases the mediastinum. The radiation dose ranged from 5600cGy to 6600cGy. Mean follow up was 42 months. The overall survival at 36 months was 89.5% (95% CI, 76.7-100). Two patients with unresectable anaplastic thyroid cancer died from progressive disease. Loco-regional control rate at 36 months was 78.9% (95% CI, 62.6-99.6). No grade 3 or 4 toxicities were reported during treatment. Conclusions: IMRT with or without concurrent chemotherapy provided excellent loco regional control and might have contributed to improved overall survival in patients with locally advanced thyroid cancer.
Author Correction: The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity
Authors: Cyril Seillet, Kylie Luong, Julie Tellier, Nicolas Jacquelot, Rui Dong Shen, Peter Hickey, Verena C. Wimmer, Lachlan Whitehead, Kelly Rogers, Gordon K. Smyth, Alexandra L. Garnham, Matthew E. Ritchie, Gabrielle T. Belz
Journal: Nature Immunology (2020)
Detection of Caga Expression in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma—Biologic Significance and Clinical Implication
Authors: S. Kuo, L. Chen, C. Lin, M. Wu, P. Hsu, Y. Tzeng, H. Tsai, H. Wang, K. Yeh, A. Cheng
Journal: Annals of Oncology (2012)
Annals Graphic Medicine - How Do You Die of Forgetting?
Authors: Sharon Rosenzweig, Peggy Mason
Journal: Annals of Internal Medicine (2020)

Web Exclusives4 February 2020Annals Graphic Medicine - How Do You Die of Forgetting?FREESharon Rosenzweig, BFA, MFA and Peggy Mason, PhDSharon Rosenzweig, BFA, MFAAffiliation (S.R., P.M.)Search for more papers by this author and Peggy Mason, PhDAffiliation (S.R., P.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0018 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Adam KortowskiSolo Internist27 March 2020 Totally amazing Congratulations for this amazing graphic. Author, Article, and Disclosure InformationAffiliations: Affiliation (S.R., P.M.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0018.Author/Illustrator Information: Sharon Rosenzweig is an investigative cartoonist (thecomictorah.com). Peggy Mason, PhD, is a professor of neurobiology at the University of Chicago. Her research centers on empathy and helping in rats. See https://thebrainissocool.com/ for more.This article was published at Annals.org on 28 January 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 February 2020Volume 172, Issue 3Page: W55-W60KeywordsConflicts of interestDisclosureHealth care ePublished: 28 January 2020 Issue Published: 4 February 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Over 200 patients recalled amid concerns that surgeon did unnecessary operations
Authors: Clare Dyer
Journal: BMJ (2020)

More than 200 patients of an orthopaedic surgeon who practised at a private hospital where the rogue breast surgeon Ian Paterson worked have been recalled amid concerns that patients may have had inappropriate or unnecessary operations.

Spire Parkway Hospital has recalled 217 patients of Habib Rahman for independent investigation of shoulder manipulation procedures carried out under general anaesthetic.

Rahman works in the NHS as a consultant orthopaedic surgeon for University Hospitals Birmingham NHS Foundation Trust. The trust confirmed that it had not recalled any …
Concomitant Chemoradiotherapy (CT/RT) or CETUXIMAB/RT (CET/RT) with or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer (LASCCHN). Preliminary Toxicity Results of a Randomized, 2x2 Factorial, Phase II-III Study. (NCT01086826)
Authors: M.G. Ghi, A. Paccagnella, D. Ferrari, M. Cossu Rocca, E. Verri, F. Morelli, G. Azzarello, C. D'Ambrosio, C. Casanova, I.C. Floriani
Journal: Annals of Oncology (2012)
Causes and predictors of early mortality in patients treated with left ventricular assist device implantation in the European Registry of Mechanical Circulatory Support (EUROMACS)
Authors: Sakir Akin, Osama Soliman, Theo M. M. H. de By, Rahatullah Muslem, Jan G. P. Tijssen, Felix Schoenrath, Bart Meyns, Jan F. Gummert, Paul Mohacsi, Kadir Caliskan
Journal: Intensive Care Medicine (2020)

The aim of the study was to analyze early mortality after continuous-flow left ventricular assist device (LVAD) implantation which remains high. We analyzed consecutive (n = 2689) patients from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) undergoing continuous-flow LVAD implantation. The primary outcome was early (< 90 days) mortality. Secondary outcomes were differential causes of early post-operative death following LVAD implantation. Univariable and multivariable analysis as well as regression analysis were used to examine determinants and differential causes of early (< 90 days) mortality after LVAD implantation. During the first 90 days, 2160 (80%) patients were alive with ongoing LVAD support, 40(2%) patients underwent heart transplantation, and 487(18%) deceased. The main causes of early death were MOF (36%), sepsis (28%), cardiopulmonary failure (CPF; 10%), CVA (9%), and right-sided heart failure (RHF, 8%). Furthermore, MOF and sepsis are 70% of causes of death in the first week. Independent clinical predictors of early death were age, female sex, INTERMACS profile 1 to 3, and ECMO. Laboratory predictors included elevated serum creatinine, total bilirubin, lactate, and low hemoglobin. Furthermore, hemodynamic predictors included elevated RA-to-PCWP ratio, pulmonary vascular resistance, and low systemic vascular resistance. Longer total implantation time was also independent predictor of early mortality. A simple model of 12 variables predicts early mortality following LVAD implantation with a good discriminative power with area under the curve of 0.75. In the EUROMACS registry, approximately one out of five patients die within 90 days after LVAD implantation. Early mortality is primarily dominated by multiorgan failure followed by sepsis. A simple model identifies important parameters which are associated with early mortality following LVAD implantation.
PD-L1はHIF-1αの新規直接ターゲットであり,低酸素症下での遮断はMDSC媒介T細胞活性化を高めた | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Noman Muhammad Zaeem, Desantis Giacomo, Janji Bassam, Hasmim Meriem, Karray Saoussen, Dessen Philippe, Bronte Vincenzo, Chouaib Salem
Journal: The Journal of Experimental Medicine (2014)
Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
Authors: Dawei Chen, Hari Menon, Vivek Verma, Chunxiao Guo, Rishab Ramapriyan, Hampartsoum Barsoumian, Ahmed Younes, Yun Hu, Mark Wasley, Maria Angelica Cortez, James Welsh
Journal: Journal for ImmunoTherapy of Cancer (2020)

This study compared response rates and outcomes of combined radiotherapy and immunotherapy (iRT) based on the type of checkpoint inhibitor (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) vs antiprogrammed death-1 (PD1)) for metastatic non-small cell lung cancer (mNSCLC).We retrospectively reviewed two prospective trials of radiation combined with anti-CTLA4 or anti-PD1 for patients with mNSCLC. Patients undergoing non-salvage stereotactic body radiation therapy (SBRT) to lung sites were selected from both trials and grouped by the immunotherapeutic compound received. Endpoints included in-field and out-of-field response rates, and overall response rate (complete or partial response) (all by response evaluation criteria in solid tumors). Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method.Median follow-up times for the 33 patients (n=17 SBRT+anti-CTLA4, n=16 SBRT+anti-PD1) were 19.6 and 19.9 months. Response rates for out-of-field lesions were similar between anti-PD1 (37%) and anti-CTLA4 (24%) (p=0.054). However, global response rates for all lesions were 24% anti-CTLA4 vs 56% anti-PD1 (p=0.194). The PFS was 76% for anti-CTLA4 vs 94% anti-PD1 at 3 months, 52% vs 87% at 6 months, 31% vs 80% at 12 months, and 23% vs 63% at 18 months (p=0.02). Respective OS values were 76% vs 87% at 6 months, 47% vs 80% at 12 months, and 39% vs 66% at 18 months (p=0.08).Both anti-CTLA4 and anti-PD1 agents prompt a similar degree of in-field and out-of-field responses after iRT, although the global response rate and PFS were statistically higher in the anti-PD1 cohort. Further dedicated study and biological mechanistic assessment is required.NCT02239900 and NCT02444741.
A Retrospective Study of Metastasectomy in Metastatic Renal Cell Carcinoma
Authors: A. Suder, K. Thillai, S. Rudman, A. Chandra, G. Rottenberg, B. Challacombe, G. Kooiman, P. Srinivasan, T. O'Brien, S. Chowdhury
Journal: Annals of Oncology (2012)
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Authors: Wendy B.C. Stevens, Katerina Bakunina, Marloes Cuijpers, Martine Chamuleau, Aart Beeker, Rob Fijnheer, Holger Hebart, Hein P.J. Visser, Jeanette K. Doorduijn, Kim Linton, Martin Dreyling, Daphne de Jong, Marie José Kersten
Journal: HemaSphere (2020)

Supplemental Digital Content is available in the text